• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在加拿大，作为 CANWARD 监测研究的一部分，从尿路感染患者中分离的大肠杆菌对磷霉素的体外活性。

In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.

机构信息

Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada.

出版信息

Antimicrob Agents Chemother. 2014;58(2):1252-6. doi: 10.1128/AAC.02399-13. Epub 2013 Dec 9.

DOI:10.1128/AAC.02399-13
PMID:24323476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3910835/
Abstract

We tested 868 urinary isolates of Escherichia coli collected from 2010 to 2013 as part of the Canadian national surveillance study CANWARD against fosfomycin by using the Clinical and Laboratory Standards Institute (CLSI) agar dilution method with MIC interpretation in accordance with the CLSI M100-S23 (2013) criteria. The concentrations of fosfomycin inhibiting 50 and 90% of the isolates were ≤1 and 4 μg/ml; 99.4% of the isolates were susceptible to fosfomycin.

摘要

我们测试了 2010 年至 2013 年期间作为加拿大国家监测研究 CANWARD 的一部分收集的 868 株来自大肠埃希菌的尿分离株对磷霉素的耐药性，采用临床和实验室标准协会（CLSI）琼脂稀释法，根据 CLSI M100-S23（2013）标准进行 MIC 解释。抑制 50%和 90%分离株的磷霉素浓度分别为≤1 和 4μg/ml；99.4%的分离株对磷霉素敏感。

相似文献

1
In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.在加拿大，作为 CANWARD 监测研究的一部分，从尿路感染患者中分离的大肠杆菌对磷霉素的体外活性。
Antimicrob Agents Chemother. 2014;58(2):1252-6. doi: 10.1128/AAC.02399-13. Epub 2013 Dec 9.
2
In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016.加拿大门诊患者 2007-2016 年经验性口服一线和二线抗菌药物治疗的尿大肠埃希菌分离株的体外药敏监测结果：CANWARD 监测研究结果。
Int J Antimicrob Agents. 2019 Jul;54(1):62-68. doi: 10.1016/j.ijantimicag.2019.04.012. Epub 2019 Apr 26.
3
Fosfomycin resistance mediated by fos genes remains rare among extended-spectrum beta-lactamase-producing Escherichia coli clinical isolates recovered from the urine of patients evaluated at Canadian hospitals (CANWARD, 2007-2017).在加拿大医院评估的患者尿液中分离的产超广谱β-内酰胺酶的大肠埃希菌临床分离株中，fos 基因介导的磷霉素耐药仍然很少见（CANWARD，2007-2017）。
Diagn Microbiol Infect Dis. 2020 Mar;96(3):114962. doi: 10.1016/j.diagmicrobio.2019.114962. Epub 2019 Dec 5.
4
[Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].[根据美国临床和实验室标准协会（CLSI）及欧洲抗菌药物敏感性试验委员会（EUCAST）建议，产超广谱β-内酰胺酶的尿源大肠埃希菌分离株对磷霉素的敏感性]
Mikrobiyol Bul. 2014 Oct;48(4):545-55.
5
Rapid detection of fosfomycin resistance in Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections.从尿路感染分离出的大肠杆菌和克雷伯菌属菌株中磷霉素耐药性的快速检测。
J Microbiol Methods. 2021 Sep;188:106296. doi: 10.1016/j.mimet.2021.106296. Epub 2021 Jul 30.
6
Experiences in fosfomycin susceptibility testing and resistance mechanism determination in Escherichia coli from urinary tract infections in the UK.英国尿路感染大肠埃希菌磷霉素药敏试验及耐药机制研究的体会。
J Med Microbiol. 2019 Feb;68(2):161-168. doi: 10.1099/jmm.0.000901. Epub 2018 Dec 13.
7
Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.磷霉素对尿路感染患者分离的大肠埃希菌和克雷伯菌属的药效学评价及pH对磷霉素活性的影响
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.02498-16. Print 2017 Aug.
8
In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study.2007 年至 2020 年加拿大尿液分离菌的体外药敏研究：CANWARD 监测研究。
J Antimicrob Chemother. 2022 Oct 28;77(11):3035-3038. doi: 10.1093/jac/dkac275.
9
Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases.携带超广谱β-内酰胺酶和AmpCβ-内酰胺酶的大肠埃希菌分离株中磷霉素耐药性的出现。
Acta Microbiol Immunol Hung. 2018 Mar 1;65(1):15-25. doi: 10.1556/030.64.2017.030. Epub 2017 Nov 15.
10
[In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].磷霉素氨丁三醇治疗大肠埃希菌相关性单纯性尿路感染的体外活性
Mikrobiyol Bul. 2009 Oct;43(4):645-9.

引用本文的文献

1
Efficacy of fosfomycin compared to second generation cephalosporin flumarin as antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: a single center retrospective study.磷霉素与第二代头孢菌素头孢替唑预防经直肠超声引导前列腺活检的疗效比较：单中心回顾性研究。
BMC Urol. 2023 Dec 19;23(1):211. doi: 10.1186/s12894-023-01391-7.
2
Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-Positive and Isolated From Urine of Pediatric Patients.产 ESBL 阳性大肠埃希菌和肺炎克雷伯菌对磷霉素和呋喃妥因的敏感性及其从儿科患者尿液中分离。
J Korean Med Sci. 2023 Dec 11;38(48):e361. doi: 10.3346/jkms.2023.38.e361.
3
Prevalence and Antibiotic Resistance Characteristics of Extraintestinal Pathogenic among Healthy Chickens from Farms and Live Poultry Markets in China.中国养殖场和活禽市场健康鸡群中肠道外致病性的流行情况及抗生素耐药特征
Animals (Basel). 2021 Apr 13;11(4):1112. doi: 10.3390/ani11041112.
4
Pharmacological Interventions for Bacterial Prostatitis.细菌性前列腺炎的药物治疗干预措施。
Front Pharmacol. 2020 Apr 30;11:504. doi: 10.3389/fphar.2020.00504. eCollection 2020.
5
Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections.口服及静脉注射磷霉素治疗复杂性尿路感染
Can J Infect Dis Med Microbiol. 2020 Mar 28;2020:8513405. doi: 10.1155/2020/8513405. eCollection 2020.
6
Antibiotic prophylaxis for transrectal ultrasound-guided prostate needle biopsy: Compared efficacy of ciprofloxacin vs. the ciprofloxacin/fosfomycin tromethamine combination.经直肠超声引导下前列腺穿刺活检的抗生素预防：环丙沙星与环丙沙星/磷霉素氨丁三醇联合用药的疗效比较
Can Urol Assoc J. 2020 Aug;14(8):267-272. doi: 10.5489/cuaj.6248.
7
Antibiotic resistance of Escherichia coli isolated from uncomplicated UTI in general practice patients over a 10-year period.10 年间普通科门诊治疗单纯性尿路感染患者分离大肠埃希菌的抗生素耐药性。
Eur J Clin Microbiol Infect Dis. 2019 Nov;38(11):2151-2158. doi: 10.1007/s10096-019-03655-3. Epub 2019 Aug 22.
8
In vitro effect of fosfomycin on multi-drug resistant gram-negative bacteria causing urinary tract infections.磷霉素对引起尿路感染的多重耐药革兰氏阴性菌的体外作用。
Infect Drug Resist. 2019 Jul 9;12:2005-2013. doi: 10.2147/IDR.S207569. eCollection 2019.
9
Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant causing urinary tract infections.磷霉素、呋喃妥因和黏菌素对碳青霉烯类耐药 引起的尿路感染的药敏谱、耐药机制和疗效比。
Indian J Med Res. 2019 Feb;149(2):185-191. doi: 10.4103/ijmr.IJMR_2086_17.
10
Community-Acquired Urinary Tract Infection by in the Era of Antibiotic Resistance.社区获得性耐药淋病奈瑟菌尿路感染。
Biomed Res Int. 2018 Sep 26;2018:7656752. doi: 10.1155/2018/7656752. eCollection 2018.

本文引用的文献

1
Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates.血源和尿源大肠埃希菌中磷霉素耐药基因的流行情况及其分子流行病学研究。
J Med Microbiol. 2013 Nov;62(Pt 11):1707-1713. doi: 10.1099/jmm.0.062653-0. Epub 2013 Aug 29.
2
Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study.加拿大医院 22746 株病原体的抗菌药敏试验结果：CANWARD 2007-11 研究结果。
J Antimicrob Chemother. 2013 May;68 Suppl 1:i7-22. doi: 10.1093/jac/dkt022.
3
Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.5 年间加拿大医院分离的产超广谱β-内酰胺酶、AmpC 酶和碳青霉烯酶大肠埃希菌和肺炎克雷伯菌的分子流行病学研究：CANWARD 2007-11。
J Antimicrob Chemother. 2013 May;68 Suppl 1:i57-65. doi: 10.1093/jac/dkt027.
4
Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.磷霉素治疗多重耐药菌引起的尿路感染的经验。
Antimicrob Agents Chemother. 2012 Nov;56(11):5744-8. doi: 10.1128/AAC.00402-12. Epub 2012 Aug 27.
5
In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010.2000 年至 2010 年美国门诊患者尿液中产大肠埃希菌的体外抗菌耐药性。
Antimicrob Agents Chemother. 2012 Apr;56(4):2181-3. doi: 10.1128/AAC.06060-11. Epub 2012 Jan 17.
6
Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.磷霉素：对革兰氏阴性病原体出现抗微生物耐药性的已发表证据的评估。
J Antimicrob Chemother. 2012 Feb;67(2):255-68. doi: 10.1093/jac/dkr466. Epub 2011 Nov 16.
7
Fosfomycin: an old--new antibiotic.磷霉素：一种老药新用的抗生素。
Clin Microbiol Infect. 2012 Jan;18(1):4-7. doi: 10.1111/j.1469-0691.2011.03636.x. Epub 2011 Sep 13.
8
Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study.2007 年至 2009 年加拿大尿路感染病原体的抗微生物药物耐药性：CANWARD 监测研究。
Antimicrob Agents Chemother. 2011 Jul;55(7):3169-75. doi: 10.1128/AAC.00066-11. Epub 2011 May 2.
9
Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.台湾一家教学医院中产超广谱β-内酰胺酶的大肠埃希菌和肺炎克雷伯菌对磷霉素和呋喃妥因的药敏性。
J Microbiol Immunol Infect. 2011 Oct;44(5):364-8. doi: 10.1016/j.jmii.2010.08.012. Epub 2011 Jan 20.
10
International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.国际临床实践指南：女性急性单纯性膀胱炎和肾盂肾炎的治疗（2010 年更新）：美国传染病学会和欧洲临床微生物学和传染病学会。
Clin Infect Dis. 2011 Mar 1;52(5):e103-20. doi: 10.1093/cid/ciq257.